Skip to main
AMPH

Amphastar Pharma (AMPH) Stock Forecast & Price Target

Amphastar Pharma (AMPH) Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 17%
Buy 0%
Hold 83%
Sell 0%
Strong Sell 0%

Bulls say

Amphastar Pharma is seeing a decline in Baqsimi sales due to lower selling prices and changes in the channel mix, which has resulted in an overall decrease in revenue for the company. However, the company's launch of ipratropium bromide HFA in 2Q26 and continued growth in prescriptions for Baqsimi show potential for future revenue growth. Despite current challenges, Amphastar's diverse product portfolio, strong presence in major markets like the U.S., China, and France, and its focus on developing challenging generic and proprietary products make it a promising stock option.

Bears say

Amphastar Pharma is facing multiple issues both with current product declines and potential product launches. With recent pricing headwinds impacting Baqsimi's sales growth expectation, it remains unclear when the company's pipeline opportunities will translate into actual revenue growth, making it difficult to project top-line and EBITDA growth. Additionally, the significant stock ownership of company directors and executive officers may lead to potential conflicts of interest and influence over important corporate decisions. Overall, these factors contribute to a negative outlook on Amphastar Pharma's stock.

Amphastar Pharma (AMPH) has been analyzed by 6 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 0% recommend Buy, 83% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amphastar Pharma (AMPH) Forecast

Analysts have given Amphastar Pharma (AMPH) a Hold based on their latest research and market trends.

According to 6 analysts, Amphastar Pharma (AMPH) has a Hold consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amphastar Pharma (AMPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.